Voyager Therapeutics (NASDAQ:VYGR) Upgraded at Truist Financial

Truist Financial upgraded shares of Voyager Therapeutics (NASDAQ:VYGR) to a strong-buy rating in a research note released on Wednesday morning,Zacks.com reports.

VYGR has been the topic of several other research reports. HC Wainwright reissued a “buy” rating and issued a $25.00 price target on shares of Voyager Therapeutics in a report on Tuesday, March 17th. Wall Street Zen upgraded Voyager Therapeutics from a “sell” rating to a “hold” rating in a research note on Saturday, March 14th. One investment analyst has rated the stock with a Strong Buy rating, two have given a Buy rating and one has assigned a Sell rating to the company. According to MarketBeat, the stock presently has a consensus rating of “Moderate Buy” and a consensus target price of $16.50.

Voyager Therapeutics Stock Down 4.1%

Shares of NASDAQ:VYGR opened at $3.96 on Wednesday. The company has a market cap of $236.02 million, a PE ratio of -1.95 and a beta of 1.32. Voyager Therapeutics has a fifty-two week low of $2.64 and a fifty-two week high of $5.55. The firm has a 50-day simple moving average of $3.91 and a 200 day simple moving average of $4.19.

Voyager Therapeutics (NASDAQ:VYGR) last issued its earnings results on Monday, March 9th. The company reported ($0.46) EPS for the quarter, beating analysts’ consensus estimates of ($0.54) by $0.08. The company had revenue of $13.46 million during the quarter, compared to the consensus estimate of $10.49 million. Voyager Therapeutics had a negative return on equity of 51.35% and a negative net margin of 296.53%. As a group, research analysts forecast that Voyager Therapeutics will post -0.91 EPS for the current fiscal year.

Insider Activity at Voyager Therapeutics

In other news, CEO Alfred Sandrock sold 14,197 shares of Voyager Therapeutics stock in a transaction that occurred on Tuesday, February 24th. The stock was sold at an average price of $3.79, for a total transaction of $53,806.63. Following the sale, the chief executive officer owned 484,060 shares of the company’s stock, valued at approximately $1,834,587.40. The trade was a 2.85% decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which is accessible through the SEC website. Insiders have sold a total of 49,783 shares of company stock valued at $188,694 in the last quarter. 6.39% of the stock is currently owned by company insiders.

Institutional Trading of Voyager Therapeutics

Several large investors have recently added to or reduced their stakes in VYGR. Wexford Capital LP bought a new stake in Voyager Therapeutics during the 3rd quarter valued at $42,000. ProShare Advisors LLC bought a new position in shares of Voyager Therapeutics in the fourth quarter worth $44,000. CIBC Asset Management Inc bought a new position in shares of Voyager Therapeutics in the fourth quarter worth $45,000. Coldstream Capital Management Inc. acquired a new position in shares of Voyager Therapeutics during the third quarter valued at $55,000. Finally, EHP Funds Inc. acquired a new position in shares of Voyager Therapeutics during the third quarter valued at $58,000. 48.03% of the stock is currently owned by institutional investors and hedge funds.

About Voyager Therapeutics

Voyager Therapeutics, Inc is a clinical-stage biotechnology company focused on the development of gene therapies for serious neurological diseases. The company’s core activities center on the design and delivery of engineered adeno-associated viral (AAV) vectors tailored to target cells in the brain and central nervous system. Through its proprietary CapsidMap and VectorMap platforms, Voyager aims to enhance vector potency, specificity and durability to address diseases with high unmet medical need.

The firm’s pipeline includes several AAV-based candidates in preclinical and early clinical development.